Moolec Science SA Regains Compliance with All Nasdaq Capital Market Continued Listing Requirements Within Panel Remediation Period
Rhea-AI Summary
Moolec Science (Nasdaq: MLEC) reported that it has regained compliance with all Nasdaq Capital Market continued listing requirements related to minimum stockholders' equity within the Panel’s remediation period.
According to Moolec, unaudited stockholders' equity was approximately $15.2 million as of December 31, 2025 and $11.3 million as of March 31, 2026. These figures reflect a partial conversion of preference shares into ordinary shares valued at about $5.47 million and pro forma adjustments for a related-party credit line disbursement of roughly $0.47 million. Moolec indicates it expects to request conversion of the remaining $4.0 million preference share balance within 12 months, which it expects would further strengthen stockholders' equity.
Positive
- Regained compliance with all Nasdaq Capital Market continued listing requirements tied to stockholders' equity
- Reported stockholders' equity of approximately $15.2 million at December 31, 2025
- Reported stockholders' equity of approximately $11.3 million at March 31, 2026 while meeting Nasdaq equity criteria
- Preference share conversion added approximately $5.47 million to equity as of December 31, 2025
- Company expects remaining $4.0 million preference shares to convert within 12 months, which it expects will strengthen equity
Negative
- Total equity decreased from about $15.2 million to $11.3 million between December 31, 2025 and March 31, 2026
- Total liabilities increased from about $88.2 million to $93.4 million over the same period
- Borrowings rose from about $45.7 million to $50.6 million between December 31, 2025 and March 31, 2026
- Convertible notes outstanding increased from about $20.7 million to $21.0 million
- Pro forma disbursements of roughly $0.47 million were drawn from a related-party line of credit in April 2026
News Market Reaction – MLEC
In the May 14 session, MLEC gained 1.68%, reflecting a mild positive market reaction. Argus tracked a peak move of +14.6% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 29 | GLASO1 industrialization | Positive | +4.5% | Completion of first GLASO1 industrialization phase with commercial-scale GLA output. |
| Apr 07 | R&D breakthrough | Positive | -4.8% | Successful stable expression of bovine myoglobin in pea seeds platform project. |
| Feb 13 | GLASO1 performance | Positive | +69.2% | Commercial-scale GLASO1 campaign delivering high GLA concentration and higher yields. |
| Jan 30 | Nasdaq conditions | Positive | -17.4% | Nasdaq Panel granted continued listing, imposing timelines and compliance conditions. |
| Jan 23 | Nasdaq exception memo | Positive | -5.1% | Nasdaq Staff memo supporting exception after large derecognition gains and equity uplift. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive operational or listing-related updates have produced mixed reactions, with more divergence than alignment between news tone and 24h price moves.
Over the last few months, Moolec has combined operational milestones with listing compliance efforts. In January 2026, Nasdaq granted continued listing subject to Panel conditions and supported an exception tied to balance-sheet improvements from derecognition gains and equity conversions. Subsequent news through February–April 2026 focused on GLASO1 commercialization and a molecular farming breakthrough. Today’s confirmation of meeting Nasdaq stockholders’ equity requirements follows directly from that earlier derecognition and equity-conversion work.
Key Terms
stockholders' equity financial
Nasdaq Capital Market regulatory
Form 6-K regulatory
convertible notes financial
warrant liabilities financial
lease liabilities financial
line of credit financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
GEORGE TOWN, CAYMAN ISLANDS / ACCESS Newswire / May 13, 2026 / As previously reported on January 29, 2026, Moolec Science SA ("Moolec" and/or the "Company"), received written notice from the Nasdaq Hearings Panel (the "Panel") informing the Company that the Panel had granted the Company's request for an extension to regain compliance with the continued listing requirements of The Nasdaq Stock Market LLC, specifically with respect to the minimum stockholders' equity requirement.
The Company announced today that it has submitted information required to demonstrate compliance with the Nasdaq Capital Market's stockholders' equity requirement within the remediation period granted by the Panel. The Company reported stockholders' equity of approximately
Preliminary Consolidated Condensed Balance Sheet as of March 31, 2026
(Unaudited)
Unaudited historical financial information MLEC as of December 31, 2025 | Unaudited preliminary financial information MLEC as of March 31, 2026 | |||||||
(amounts in millions of US$) | ||||||||
Assets | ||||||||
Intangible assets | 71.6 | 71.6 | ||||||
Goodwill | 2.1 | 2.1 | ||||||
Property, plant and equipment | 4.4 | 4.4 | ||||||
Investment in joint ventures and associates | 16.0 | 16.0 | ||||||
Cash and cash equivalents | 1.0 | 1.2 | ||||||
Inventories | 4.0 | 3.6 | ||||||
Other receivables | 4.2 | 5.2 | ||||||
Right of use assets | 0.1 | - | ||||||
Total assets | 103.4 | 104.2 | ||||||
Equity | ||||||||
Total equity | 15.2 | 11.3 | ||||||
Liabilities | ||||||||
Borrowings | 45.7 | 50.6 | ||||||
Convertible notes | 20.7 | 21.0 | ||||||
Trade and other payables | 7.1 | 7.2 | ||||||
Other liabilities | 0.3 | 0.3 | ||||||
Deferred tax liabilities | 14.3 | 14.3 | ||||||
Warrant liabilities | 0.1 | 0.3 | ||||||
Lease liabilities | 0.1 | - | ||||||
Total liabilities | 88.2 | 93.4 | ||||||
Total equity and liabilities | 103.4 | 104.7 | ||||||
Underlying Assumptions
Derecognition Events
The Company assumed the full derecognition of Bioceres S.A. and Bioceres LLC as of December 31, 2025 and determined that the carrying value of the Company's investment in Theo I SCSp was nil.
Preference Shares Capitalization
The holder of our preference shares issued a notice of conversion to the Company dated December 31, 2025, notifying the Company of the partial exercise of its conversion right under the Subscription Agreement dated December 9, 2024 an aggregate amount of up to
The Company also included as of March 31, 2026 the proforma adjustment related to disbursements made from our current line of credit with one of our related parties for an amount of
Furthermore, the Company expects to notify the holder to convert the remaining
Forward-looking Statements
This press release contains "forward-looking statements." Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to the Company's plan to regain compliance under the Nasdaq rules and the related Nasdaq decision, performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec's business and other risks and uncertainties, including those included under the header "Risk Factors" in Moolec's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ("SEC"), as well as Moolec's other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.
Moolec Science's Contacts:
SOURCE: Moolec Science
View the original press release on ACCESS Newswire